Search Within

Juha P Himanen

Formats
  1. Journal Article (48)
  2. Book Section (1)
  3. Review (1)
Groups
  1. Sloan Kettering Institute Postdocs (50)
  2. GSK Faculty (45)
  3. Sloan Kettering Institute Faculty (45)
  4. Structural Biology Program Faculty (44)
  5. Cancer Biology and Genetics Program Faculty (2)
  6. Radiochemistry and Imaging Sciences Service (2)

More Groups

People
  1. Dimitar Nikolov (44)
  2. Nayanendu Saha (10)
  3. Yehuda Goldgur (10)
  4. Dorothea Robev (8)
  5. Kai Xu (8)
  6. William Barton (6)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2022 (1)
  4. 2021 (3)
  5. 2020 (1)
  6. 2019 (1)

More Years

Publications
  1. Protein Science (4)
  2. Journal of Biological Chemistry (3)
  3. Proceedings of the National Academy of Sciences of the United States of America (3)
  4. Acta Crystallographica Section D: Biological Crystallography (2)
  5. Biochemical and Biophysical Research Communications (2)
  6. Cell (2)

More Publications

Publishers
  1. Elsevier Inc. (8)
  2. Wiley Blackwell (8)
  3. Elsevier Science, Inc. (4)
  4. Nature Publishing Group (4)
  5. American Society for Biochemistry and Molecular Biology (3)
  6. Cell Press (3)

More Publishers

Results (50)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Fully human monoclonal antibody targeting the cysteine-rich substrate-interacting region of ADAM17 on cancer cells
    Journal Article

    Saha, N.; Lee, S. G.; Brockmann, E. C.; de la Cruz, M. J.; Goldgur, Y.; Mendoza, R. P.; de Stanchina, E.; Love, T. M.; Marvald, J.; Xu, Y.; more...
    Biomedicine and Pharmacotherapy (2024)

    Fulltext@MSK | Save
  • Time-resolved live-cell spectroscopy reveals EphA2 multimeric assembly
    Journal Article

    Shi, X.; Lingerak, R.; Herting, C. J.; Ge, Y.; Kim, S.; Toth, P.; Wang, W.; Brown, B. P.; Meiler, J.; Sossey-Alaoui, K.; more...
    Science (2023)

    Fulltext@MSK | Save
  • Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells
    Journal Article

    Saha, N.; Xu, K.; Zhu, Z.; Robev, D.; Kalidindi, T.; Xu, Y.; Himanen, J.; de Stanchina, E.; Pillarsetty, N. V. K.; Dimitrov, D. S.; more...
    Translational Oncology (2022)

    Fulltext@MSK | Save
  • The EphB2 receptor uses homotypic, head-to-tail interactions within its ectodomain as an autoinhibitory control mechanism
    Journal Article

    Xu, Y.; Robev, D.; Saha, N.; Wang, B.; Dalva, M. B.; Xu, K.; Himanen, J. P.; Nikolov, D. B.
    International Journal of Molecular Sciences (2021)

    Fulltext@MSK | Save
  • Ephrin-A1 and the sheddase ADAM12 are upregulated in COVID-19
    Journal Article

    Mendoza, R.; Saha, N.; Momeni, A.; Gabutan, E.; Alawad, M.; Dehghani, A.; Diks, J.; Lin, B.; Wang, D.; Alshal, M.; more...
    Heliyon (2021)

    Fulltext@MSK | Save
  • Structure of the EphB6 receptor ectodomain
    Journal Article

    Mason, E. O.; Goldgur, Y.; Robev, D.; Freywald, A.; Nikolov, D. B.; Himanen, J. P.
    PLoS ONE (2021)

    Fulltext@MSK | Save
  • From genetic data and structures to drug development: New approaches to target Eph receptors
    Book Section

    Nikolov, D. B.; Himanen, J. P.
    In Freywald, A.; Vizeacoumar, F. J. (Eds.) Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance (2020)

    Fulltext@MSK | Save
  • ADAM proteases: Emerging role and targeting of the non-catalytic domains
    Review

    Saha, N.; Robev, D.; Himanen, J. P.; Nikolov, D. B.
    Cancer Letters (2019)

    Fulltext@MSK | Save
  • Therapeutic potential of targeting the Eph/ephrin signaling complex
    Journal Article

    Saha, N.; Robev, D.; Mason, E. O.; Himanen, J. P.; Nikolov, D. B.
    International Journal of Biochemistry and Cell Biology (2018)

    Fulltext@MSK | Save
  • Binding of EphrinA5 to RET receptor tyrosine kinase: An in vitro study
    Journal Article

    Liu, Y.; Kaljunen, H.; Pavić, A.; Saarenpää, T.; Himanen, J. P.; Nikolov, D. B.; Goldman, A.
    PLoS ONE (2018)

    Fulltext@MSK | Save